Perjeta is a personalised medicine approved by the FDA and EC in combination with Herceptin (trastuzumab) for the treatment of patients with previously untreated HER2-positive metastatic breast cancer.
Perjeta is designed to prevent the HER2 receptor from pairing with other HER receptors on the surface of cells, a mechanism that is complementary to Herceptin. Used together the combination is thought to provide a more comprehensive blockade of HER signalling pathways.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions. See our information for details on how to report.